American Society of Clinical Oncology

Abstract

distinct and molecular subtypes lymphoma (DLBCL): (GCB) lymphoma, clinical and clinical trials identifying who in a high-risk Stomatitis occurs in approximately 65% of patients who are being treated with everolimus. Dr. Rugo’s meta-analysis of seven clinical trials looked at a total of 1,455 patients, 973 of whom developed stomatitis—89% within eight weeks of initiat-ing therapy. Forty percent of patients had a second onset of stomatitis. The dose of everolimus used in each of the seven trials was 10 mg/day. Bevacizumab targets vascular endothelial growth factor (VEGF)-blocking angiogenesis, and cetuximab blocks epider-mal growth factor receptor (EGFR), a protein affecting cancer growth and spread. Leukemia Oncology showed that for wild-type KRAS gene-mutated metastatic colorectal cancer patients, first-line treatment with and either of two targeted drugs, bevacizumab or cetuximab, led to similar median survival of about 29 months. re-analysis of a clinical trial taking into account the effect of large numbers of multiple myeloma patients switching to the more active treatment regimen the benefit shown in the original analysis.